Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 9/20 | 0.35 |
| ▸ | CNR1 | P21554 | 7/20 | 0.35 |
| ▸ | PARG | Q86W56 | 6/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918918 | 0.82 | CNR2 (0.55) | PLA2G2ACNR2CNR1PARGNPC1 | |
| SCHEMBL735903 | 0.80 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL3915272 | 0.72 | CNR2 (0.44) | CNR2CNR1 | |
| SCHEMBL3925596 | 0.69 | CNR2 (0.44) | CNR2CNR1 | |
| SCHEMBL4385172 | 0.68 | CNR2 (0.59) | PLA2G2ACNR2CNR1NPC1 | |
| SCHEMBL3916224 | 0.68 | CNR2 (0.59) | CNR2CNR1NPC1 | |
| SCHEMBL14261258 | 0.68 | CNR2 (0.59) | CNR2CNR1NPC1 | |
| SCHEMBL14260974 | 0.68 | CNR2 (0.59) | PLA2G2ACNR2CNR1NPC1 | |
| SCHEMBL736776 | 0.68 | CNR2 (0.51) | CNR2CNR1NPC1 | |
| SCHEMBL3925911 | 0.67 | CNR2 (0.58) | CNR2CNR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | PLA2G2A 2857/4885CNR2 3/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.